Drug interactions
Buprenorphine transdermal + Lorlatinib
Severity: Moderate
Buprenorphine transdermal and Lorlatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib is a CYP3A4 inducer and can lower buprenorphine exposure. This may reduce analgesia or provoke opioid withdrawal symptoms. When lorlatinib is stopped, buprenorphine levels may rise again.
What this interaction means in plain words
Buprenorphine transdermal and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Lorlatinib induces CYP3A4, increasing the metabolism of buprenorphine.
What to do
Monitor for loss of pain control or withdrawal and titrate the buprenorphine dose if needed. Reassess for sedation and respiratory depression after lorlatinib is discontinued.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Buprenorphine transdermal and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Buprenorphine transdermal with Lorlatinib?
MediHelp rates the interaction as moderate. Buprenorphine transdermal and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib is a CYP3A4 inducer and can lower buprenorphine exposure. This may reduce analgesia or provoke opioid withdrawal symptoms. When lorlatinib is stopped, buprenorphine levels may rise again.
How serious is the interaction between Buprenorphine transdermal and Lorlatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for loss of pain control or withdrawal and titrate the buprenorphine dose if needed. Reassess for sedation and respiratory depression after lorlatinib is discontinued.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
